A recent study in 2021 demonstrated that a combined therapy of encorafenib (a kinase inhibitor) and cetuximab (an EGFR inhibitor) increased the overall survival rate, objective response rate, and progression-free survival rate in patients who were previously treated for BRAF V600E-mutated CRC in a metastatic setting [51]. Here, BRAF is linked to colorectal carcinoma.